



Cite this: *RSC Med. Chem.*, 2022, **13**, 1549

Fragment optimization and elaboration strategies – the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits†

Christopher R. Smith, ^{*a} Svitlana Kulyk, ^{*a} Misbha Ud Din Ahmad, ^b Valentina Arkhipova, ^b James G. Christensen, ^a Robin J. Gunn, ^a Anthony Ivetac, ^a John M. Ketcham, ^a Jon Kuehler, ^a J. David Lawson, ^a Nicole C. Thomas, ^a Xiaolun Wang^a and Matthew A. Marx^a

Received 27th May 2022,
Accepted 27th August 2022

DOI: 10.1039/d2md00163b

rsc.li/medchem

Here we describe the early stages of a fragment-based lead discovery (FBLD) project for a recently elucidated synthetic lethal target, the PRMT5/MTA complex, for the treatment of *MTAP*-deleted cancers. Starting with five fragment/PRMT5/MTA X-ray co-crystal structures, we employed a two-phase fragment elaboration process encompassing optimization of fragment hits and subsequent fragment growth to increase potency, assess synthetic tractability, and enable structure-based drug design. Two lead series were identified, one of which led to the discovery of the clinical candidate MRTX1719.

Introduction

Protein arginine methyl transferase 5 (PRMT5) is an essential class II PRMT that catalyzes the symmetric transfer of two methyl groups to the arginine residues of substrate proteins using *S*-adenosyl-L-methionine (SAM) as the methyl donor.¹ In 2016, several independent research groups reported that loss of the tumor suppressor gene *CDKN2A* is commonly accompanied by co-deletion of the proximal gene encoding methylthioadenosine phosphorylase (*MTAP*).^{2–4} In turn, *MTAP* deletion causes the accumulation of the cellular metabolite methylthioadenosine (MTA). MTA is an intermediate of the methionine salvage pathway and weakly inhibits PRMT5, competing with SAM to bind in the co-factor binding site to form the PRMT5/MTA complex.⁴ It was postulated that a compound which binds to and stabilizes the PRMT5/MTA complex would inhibit PRMT5 activity in *MTAP*-null cancer cells while preserving PRMT5 activity in healthy cells and could potentially increase the therapeutic safety index in *CDKN2A/MTAP* co-deleted cancer cells relative to first generation PRMT5 inhibitors that are not selective binders of the PRMT5/MTA complex. Recently, we reported the discovery of clinical candidate MRTX1719, a small molecule that potently binds to the PRMT5/MTA complex, and inhibits PRMT5 selectively in *MTAP*-deleted HCT116 cells.⁵ Two other

groups have published patent applications^{6,7} that also appear to target the PRMT5/MTA complex, with MRTX1719 and literature examples shown in Fig. 1.

Herein we describe a fragment-based lead discovery (FBLD) program focused specifically on fragment elaboration strategies starting with five fragment hits (1–5, Table 1) supported by structure-based drug design. We outline a two-phase process. Phase 1: optimization of the fragment hit prior to fragment growth strategies, and phase 2: fragment growth to increase potency supported by the development of versatile synthetic chemistry and, exploration of growth vectors aided by structure-based drug design (SBDD). In some instances, phase 1 was skipped and efforts were immediately focused on phase 2. The five fragment hits described in Table 1 led to the discovery of two lead series.

FBLD is a hit finding and lead generation approach where libraries of fragment compounds are screened at high concentration, typically in the range 100 μ M to 1 mM.^{8,9} Libraries typically range in size from 350 to 15 000 compounds and a fragment is typically defined as a compound with between 10 and 17 heavy atoms.¹⁰ Due to the small size of the fragments, affinities are weak, thus sensitive screening methods are employed for detection. As a result of testing fragments at high concentration careful attention needs to be paid to factors such as compound aggregation, compound solubility, and pan-assay interference compounds (PAINS).¹¹ Since the first disclosure of an FBLD project in 1996,¹² commercially available, well curated fragment libraries are widely available. When we initiated our PRMT5/MTA inhibitor project, there was no evidence in the literature of compounds that were characterized to bind to the PRMT5/

^a Mirati Therapeutics, San Diego, California, 92121, USA.
E-mail: smithc@mirati.com, kulyks@mirati.com

^b ZoBio BV, J. H. Oortweg 19, 2333 CH Leiden, Netherlands

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d2md00163b>














Fig. 1 MRTX1719 and representative compound structures of PRMT5/MTA inhibitors from recently published patent applications

Table 1 Fragment hits 1–5 with PRMT5/MTA X-ray co-crystal structures

Ex.	Structure	PRMT5/MTA K_D (μM)	LE/LLE	clog P	PRMT5/MTA X-ray crystal structure	PDB
1		0.74	0.78/4.9	1.2		8CSG
2		10.2	0.54/4.9	0.1		7S0U
3		12.0	0.57/3.2	1.7		8CTB
4		62.0	0.49/3.1	1.1		7UYF
5		53.0	0.50/3.2	1.1		7UYI

MTA complex. We concluded that an FBLD screen of a commercially available fragment library against PRMT5/MTA would be a rapid and cost-effective method to identify hits. Our decision to select a fragment screen rather than a high throughput screen (HTS) or a DNA encoded library (DEL) screen was based on timelines. We did not have immediate access to HTS or DEL, but we had the capability to rapidly

run a fragment screen. The details of the fragment screen performed against PRMT5/MTA were previously described.⁵ To summarize, a commercially available fragment library was screened using surface plasma resonance (SPR) with the PRMT5 protein immobilized on the surface. Formation of the PRMT5/MTA complex was achieved by adding MTA (20 μ M) to the running buffer. 24 hits with saturable K_{D5} \leq 500 μ M

were identified. The SPR assay was designed to detect affinity for the PRMT5/MTA complex and the affinity of the compounds for PRMT5 alone was not measured. From these 24 hits, five X-ray co-crystal structures were obtained with fragments bound to the PRMT5/MTA complex. The compound structures, SPR data, LE,¹³ LLE,¹⁴ clog *P*, X-ray co-crystal structures, and PDB codes are shown in Table 1.

Fragment hit **1**, a 1*H*-pyrrolo[3,2-*b*]pyridin-5-amine scaffold, was the most potent and efficient binder identified in the screen (PRMT5/MTA K_D = 0.74 μM , LE = 0.78, LLE = 4.9). The X-ray co-crystal structure of fragment hit **1** with PRMT5/MTA (PDB: 8CSG) is shown in Fig. 2A. **1** binds in the PRMT5 substrate binding site with a series of specific interactions with the protein and MTA. The productive interactions with the protein include an H-bond between the pyrrolo N-H and the backbone carbonyl of Ser578, a bifurcated H-bond between the $-\text{NH}_2$ substituent and the backbone carbonyl of Glu435 and the side chain of Glu444, an ionic interaction between the protonated pyridinyl nitrogen and Glu444 and a halogen bond between the bromo substituent and the Glu435 side chain. Productive van der Waals interactions between MTA and **1** include the sulfur atom interacting with the $-\text{NH}_2$ and bromo substituents. The MTA methyl also makes a productive bifurcated van der Waals interaction with the bromo substituent of **1** and the CD atom of Glu435. Fragment hit **1**, along with the fragments and analogs described herein, make π -stacking interactions with Phe327 and Trp579 (Fig. 2B).

Fragment hit **2**, a 4-(aminomethyl)phthalazine-1(2*H*)-one scaffold, was the second most potent binder and despite the 38-fold lower potency compared to **1**, the LLEs for **1** and **2** were identical due to the lower lipophilicity of **2** (PRMT5/MTA K_D = 10.2 μM ; LE = 0.54, LLE = 4.9 and clog *P* = 0.1). The X-ray co-crystal structure of fragment hit **2** with PRMT5/MTA (Fig. 3; PDB: 7S0U) was previously reported.⁵ In addition to the previously described H-bond interactions the van der




Fig. 3 X-ray co-crystal structure of fragment hit **2** bound to PRMT5/MTA (PDB: 7S0U) showing H-bond interactions with Glu444, Glu435 and Lys333 and van der Waals interactions between MTA, **2** and Glu435 highlighted in grey.

Waals interactions between the sulfur atom of MTA and the primary amino group of **2** and the MTA methyl with the CD atom of Glu435 are highlighted in Fig. 3.

The binding potency of fragment hit **3**, a 1-methyl-1*H*-benzo[d]imidazol-2-amine scaffold, was almost identical to **2** (PRMT5/MTA K_D = 12.0 μM). However, due to its higher lipophilicity (clog *P* = 1.7) the LLE was lower compared to **2** (LLE = 3.2). The X-ray co-crystal structure of **3** with PRMT5/MTA (PDB: 8CTB) is shown in Fig. 4. The 7-chloro-1-methyl-1*H*-benzo[d]imidazol-2-amine fragment binds in the PRMT5 substrate binding site with a series of specific interactions closely related to fragment hit **1**. These include a bifurcated H-bond between the $-\text{NH}_2$ substituent and the backbone carbonyl of Glu435 and the side chain of Glu444, and an ionic interaction between the protonated imidazo nitrogen





Fig. 2 A) The X-ray co-crystal structure of fragment hit **1** bound to PRMT5/MTA (PDB: 8CSG) showing H-bond interactions with Glu444, Glu435 and Ser578, halogen bond interaction with Glu435 and van der Waals interactions between MTA, **1** and Glu435 highlighted in grey. B) A cutaway visual to illuminate the proximity of MTA to **1** and the π -stacking interaction between the bicyclic scaffold and the side chains of Phe327 and Trp579.






Fig. 4 X-ray co-crystal structure of fragment hit 3 bound to PRMT5/MTA (PDB: 8CTB) showing H-bond interactions with Glu444 and Glu435, van der Waals interaction between MTA and 3 in highlighted in grey and a potentially repulsive interaction with Lys333.

and the Glu444 sidechain. The sulfur atom of MTA makes a productive van der Waals interaction with the methyl and $-\text{NH}_2$ substituent of 3. There is a potentially unfavorable interaction between the sigma hole on the chlorine atom and the Lys333 sidechain. This observation highlighted a possible opportunity to optimize the fragment prior to initiating fragment growing strategies.

Fragment hits 4 and 5, a 1,5-naphthyridin-2-amine scaffold, are closely related structurally and have similar binding potencies (PRMT5/MTA K_D = 62.0 μM and 53.0 μM respectively) and their LLE values (LLE = 3.1 and 3.2 respectively) are almost identical to 3. The X-ray co-crystal structures of 4 and 5 with PRMT5/MTA (PDB: 7UYF and PDB: 7UY1) are shown in Fig. 5. The binding modes and interactions of 4 and 5 are closely related to those observed for fragment hits 1 and 3, with one notable difference—the Ser578 side chain in the fragment hit 4 X-ray co-crystal structure makes a productive H-bond interaction with the 5-naphthyridine nitrogen lone pair (Fig. 5A). Surprisingly, the Ser578 side chain and backbone loop rotate away from the

fragment in the PRMT5/MTA X-ray co-crystal structure with 5 and does not make the same Ser578 H-bond interaction as 4 (Fig. 5B). The extent of the side chain and loop movements are visualized in Fig. 5C. Given the high similarity of 4 and 5 it was not clear what was causing the loop and sidechain movement between the two structures.

The output of the fragment screen revealed several important pharmacophoric features of the PRMT5/MTA complex. First, an interconnected H-bond network between the Glu444 side chain, the Glu435 backbone carbonyl and the ligand was common to each fragment hit. In addition, each fragment hit made productive van der Waals interactions with MTA. Second, a “2-aminopyridinyl-like” motif comprised of a 2-amino substituent ortho to an aromatic nitrogen lone pair, is a pharmacophoric feature common to fragments 1, 3, 4 and 5. Third, fragment 2 is a unique pharmacophore that creates the key H-bond network with a 4-(aminomethyl)phthalazine-1(2H)-one motif. A series of other productive protein/ligand interactions were also discovered from the screen. For example, fragment hit 1 picked up an H-bond interaction with the Ser578 backbone carbonyl, fragment hit 2 picked up an H-bond interaction with the Lys333 side chain and fragment hit 4 picked up an H-bond interaction with the side chain of Ser578.

Fragment elaboration

As described above, the hits can be divided into two classes of pharmacophores: the “2-aminopyridinyl-like” pharmacophore class, represented by fragment hits 1, 3, 4 and 5 and the 4-(aminomethyl)phthalazine-1(2H)-one pharmacophore class represented by fragment hit 2. We elected to invest in the exploration of both pharmacophore classes. To explore the SAR of the “2-aminopyridinyl-like” pharmacophore we chose to combine hits 4 and 5 together due to their similarity and elaborate fragments 1, 3 and 4 concurrently. The basis for the decision to explore the SAR of three separate representatives of the “2-aminopyridinyl-like” class was supported by the observation that, despite the similarity of 1, 3 and 4, there were significant differences in




Fig. 5 A) X-ray co-crystal structure of fragment hit 4 bound to PRMT5/MTA (PDB: 7UYF) showing H-bond interactions with Glu444, Glu435 and Ser578. Van der Waals interactions between MTA and 4 are highlighted in grey. B) X-ray co-crystal structure of fragment hit 5 bound to PRMT5/MTA (PDB: 7UY1). Interactions are closely related to 4 however H-bond interaction with sidechain Ser578 not observed. C) Overlay of fragment hits 4 and 5 showing the movement of Ser578 loop and sidechains.







the geometries of their growth vectors. We speculated that these differences could lead to divergent SAR. The three divergent growth vector geometries for **1**, **3** and **4** are depicted in Fig. 6.

We developed several key questions to investigate in the first round of fragment elaboration. First, could binding potency be improved? And, if so, was the potency increase due to adding lipophilicity—the hydrophobic effect,¹⁵ or was the increase in potency driven by the ligand making additional productive interactions with the protein? Δ LLE (Δ LLE = LLE_{analog} – LLE_{parent}) is a useful analysis tool to tease this question apart.¹⁴ A positive Δ LLE suggests the analog added favorable interactions with the protein, and a negative Δ LLE suggests the loss of favorable interactions and/or the creation of unfavorable interactions or clashes with the protein. A zero Δ LLE suggests the change in potency is lipophilicity driven. Second, could tractable synthetic chemistry be developed to explore the growth vectors of interest?¹⁶ And third, could one or more additional X-ray co-crystal structures be obtained with analogs of the hit to further enable SBDD? And, if so, was the fragment binding mode and the conformation of the protein in the binding pocket reproducible? With data in hand addressing these questions, the goal was to then decide which series to elect as a lead series.

Fragment hit **1** – series **1**

The chemical reactivity of the bromo substituent of **1** created challenges to develop versatile synthetic chemistry; therefore, a series of bromo replacements including-methyl (**6**), -cyclopropyl (**7**) and -CF₃ (**8**) were investigated to optimize the fragment, shown in Table 2. The methyl analog **6** increased potency less than two-fold (PRMT5/MTA K_D = 0.46 μ M), and due to a reduction in clog *P*, LLE increased (clog *P* = 0.8; Δ LLE = +0.6). The larger and more lipophilic cyclopropyl analog **7** decreased potency and LLE

Table 2 Examples **6–8** designed to optimize fragment hit **1** at the fragment level

Ex.	Structure	PRMT5/MTA K_D (μ M)	LLE	clog <i>P</i>
1		0.74	4.9	1.2
6		0.46	5.5	0.8
7		3.3	3.9	1.6
8		11.7	3.6	1.3

(PRMT5/MTA K_D = 3.3 μ M; Δ LLE = -1.0). The -CF₃ analog **8** resulted in a 15-fold decrease in potency and a lower LLE (PRMT5/MTA K_D = 11.7 μ M; Δ LLE = -1.3). Presumably, the electron withdrawing nature of the -CF₃ substituent reduced the pK_a of the conjugate acid of the pyridinyl nitrogen lone pair, leading to a significant reduction in the potency for **8**. An X-ray co-crystal structure of **7** with PRMT5/MTA was generated and is shown in Fig. 7A. The binding mode of **7** with PRMT5/MTA is closely related to the binding mode of fragment hit **1**. Indeed, **7** makes the same H-bond interactions with the protein as fragment hit **1**. An overlay of fragment hit **1** and **7** is shown in Fig. 7B. Interestingly, the larger cyclopropyl substituent is accommodated in the binding pocket by the ligand shifting out of the pocket by approximately 0.5 \AA , as opposed to the protein moving to accommodate the increased steric volume of the cyclopropyl substituent. By the end of phase 1—optimization of the fragment hit prior to fragment growing—we were encouraged to find that the bromo substituent could be effectively replaced by a methyl substituent and that a second X-ray co-crystal structure could be obtained that maintained the original fragment binding mode.

Visual inspection of the X-ray co-crystal structure of fragments **1** and **7** revealed that the 2-position of the 1*H*-pyrrolo[3,2-*b*]pyridine scaffold was the most suitable position for fragment growth. Identifying a synthetically tractable route to rapidly explore the 2-position vector was a challenge, even with replacement of the 6-bromo substituent with a 6-methyl substituent. Therefore, a less exploratory approach not dependent on rapid parallel synthesis techniques was initiated. To create bespoke molecules for synthesis we employed SBDD molecular modeling with MOE (Molecular Operating Environment).¹⁷ An overlay of **1** with the X-ray co-crystal structure of EPZ015666,^{18,19} a first generation PRMT5 inhibitor bound to the PRMT5/SAM complex (Fig. 8A, PDB: 4X61) inspired a chimeric design, example **9**, where the methylene linked pyrimidine-4-carboxamide group of




Fig. 6 Overlay of fragments **1**, **3** and **4** with the divergent growth vectors depicted by magenta, orange and purple arrows, respectively.






Fig. 7 A) X-ray co-crystal structure of 7 bound to PRMT5/MTA (PDB: 7ZVL). B) Overlay of 7 (orange) with fragment hit 1 (magenta). 7 has the same binding mode including H-bond interactions as 1 but is shifted by 0.5 Å to accommodate the cyclopropyl substituent.




Fig. 8 A) Overlay of fragment hit 1 (magenta) onto the EPZ015666 (pink) PRMT5/SAM X-ray co-crystal structure (PDB: 4X61). B) Model of compound 9 bound in PRMT5/MTA conceived by the overlay of fragment hit 1 and EPZ015666. C) X-ray co-crystal structure of 9 bound to PRMT5/MTA (PDB: 7ZUQ). 9 adopts an alternative conformation to the model forming an H-bond between the amide carbonyl of 9 and Leu312 and water mediated H-bonds to Asn443 and Ser439. D) SBDD enabled optimization of fragment hit 1 to give compound 9.

EPZ015666 was fused to the 2-position of 1. A MOE model of 9 bound to PRMT5/MTA is shown in Fig. 8B, where the amide carbonyl group mimics the homologous moiety of EPZ015666, making a productive H-bond interaction with Phe580 backbone N-H. The potency of 9 increased 82-fold (PRMT5/MTA $K_D = 9$ nM) with an increase in LLE (Δ LLE = +2.5), Fig. 8D. This example demonstrates how powerful a chimeric approach with known ligands can be to increase the potency of a fragment. However, what is remarkable in this case is that the chimera was generated between two ligands

binding to significantly different conformations of the PRMT5 protein. The X-ray co-crystal structure of 9 in PRMT5/MTA (Fig. 8C, PDB: 7ZUQ) revealed that the binding mode of the initial fragment 1 is conserved but the methylene linker orients the amide in an alternative conformation to the conformation generated by molecular modeling. Indeed, the amide carbonyl group makes a productive H-bond interaction with Leu312 backbone N-H and a water-mediated H-bond with the Ser439 backbone N-H and the sidechain of Asn443. We noted that this result was a fortunate discovery, for it



highlighted the interaction with the Leu312 backbone N–H as a favorable interaction. This example illustrates the exploratory—and often serendipitous—nature of fragment growing strategies and highlights the value in obtaining X-ray co-crystal structures during the fragment growing process.

Fragment hit 2 – series 2

A detailed description of the optimization of fragment 2 was previously reported.⁵ In summary (Fig. 9A), versatile bromo intermediate **10** was prepared, and a series of 20 analogs were made and tested. The rapid exploration of the SAR returned compound **11** with a 2040-fold increase in binding potency and improved LLE (PRMT5/MTA K_D = 5 nM; Δ LLE = +3.5). The X-ray co-crystal structure of **11** with PRMT5/MTA (PDB 7S1Q)⁵ is shown in Fig. 9B. The initial binding mode of **2** was maintained and the *N*-methylpyrazol-4-yl substituent made a favorable H-bond interaction between the pyrazolo lone pair and the Leu312 backbone N-H. Interestingly, this is the same backbone N-H interaction that was discovered in the chimeric approach with series 1, example **9**. This example of fragment growth illustrates how a dramatic increase in binding potency can be achieved with a modest number of analogs when supported by SBDD.

Fragment hit 3 – series 3

Fragment hit **3** was the most lipophilic ($\text{clog } P = 1.7$) of the five fragment hits. Therefore, before embarking on a fragment growing strategy, optimization of the fragment was investigated. A series of analogs were designed to replace the 7-chloro substituent, reduce $\text{clog } P$ and/or make a productive interaction with the Lys333 sidechain, examples **12–18** in Table 3. LLE was tracked to assess progress. Replacement of the 7-chloro substituent with hydrogen (**12**) reduced the $\text{clog } P$ by 0.7 units, while potency dropped approximately 6-fold and the LLE was unchanged (PRMT5/MTA $K_D = 70.0 \mu\text{M}$; $\Delta \text{LLE} = 0$, $\text{clog } P = 1.0$). Exchanging the 7-chloro with a 7-nitrile substituent (**13**) reduced $\text{clog } P$ by 0.8, increased potency almost 6-fold and

Table 3 Examples 12–18 designed to optimize fragment hit 3 at the fragment level

Ex	Structure	PRMT5/MTA K_D (μM)	LLE	clog P
3		12.0	3.2	1.7
12		70.0	3.2	1.0
13		2.2	4.8	0.9
14		23.9	3.4	1.2
15		35.0	3.1	1.4
16		240	2.6	1.0
17		43.0	4.0	0.4
18		28.0	4.0	0.6

LLE increased significantly (PRMT5/MTA $K_D = 2.2 \mu\text{M}$; $\Delta\text{LLE} = +1.6$; $\text{clog}P = 0.9$). The positive LLE suggested the nitrile was making a favorable interaction with the protein. This binding hypothesis was indeed confirmed later by a series





Fig. 9 A) Discovery of compound **11** from fragment hit **2** via versatile synthetic intermediate **10**. B) X-ray co-crystal structure of **11** bound to PRMT5/MTA (PDB: 7S1Q). **11** adopts same binding mode as the original fragment hit and adds an additional H-bond interaction with Leu312.

of X-ray co-crystal structures with analogs closely related to **13**, *vide infra*. A series of 7-fluoro, 7-methyl and 7-methoxy analogs (**14–16**) were also investigated. A similar LLE was observed for **14** and **15** while a drop in LLE was observed for **16** ($\Delta\text{LLE} = +0.2$; -0.1 and -0.6 respectively). Introduction of an aza into the ring (**17**) reduced the clog *P* to 0.4 and LLE increased (PRMT5/MTA $K_D = 43.0\ \mu\text{M}$; $\Delta\text{LLE} = +0.8$). Homologation of **17** yielded *N*-ethyl analog **18** (PRMT5/MTA $K_D \text{ IC}_{50} = 28.0\ \mu\text{M}$). An X-ray co-crystal structure of **18** with PRMT5/MTA (PDB: 7ZUP) revealed that **18** maintains the same binding mode as the initial fragment, and the pyridinyl nitrogen lone pair makes a water-mediated H-bond interaction with the side chains of Lys333 and Ser578, shown in Fig. 10. With the X-ray co-crystal structures of **3** and **18** in hand, a molecular model of **13** bound to PRMT5/MTA was generated using MOE, shown in

Fig. 11A. The model indicated that the 7-nitrile substituent made a productive H-bond with the Lys333 sidechain. In summary, optimization of the fragment prior to fragment growth was successful, with an approximate 6-fold increase in potency and a 1.1-unit reduction in clog *P*. In addition, a second X-ray co-crystal structure was determined with the observation that the new structure maintained the binding mode of the original hit. Encouraged by these findings, an SBDD enabled fragment growing strategy was initiated starting with optimized fragment **13**.

By visual inspection of the PRMT5/MTA X-ray co-crystal structures of **3** and **18**, we envisioned a series of analogs at the 5-position of the 2-amino-1-methyl-1*H*-benzo[*d*]imidazolo-7-carbonitrile scaffold. Further analysis of the model of **13** with PRMT5/MTA identified two unsatisfied backbone N-Hs (Leu312 and Phe580) accessible within 6 Å of the 5-position,




Fig. 10 A) X-ray co-crystal structure of **18** bound to PRMT5/MTA (PDB: 7ZUP). **18** adopts the same binding mode as the original fragment hit **3** B) **18** picks up an additional water mediated H-bond to the side chains of Lys333 and Ser578.




Fig. 11 Model of compound **13** bound to PRMT5/MTA (A) H-bond network predicted to mimic parent fragment hit **3** with the addition of an H-bond to Lys-333 (B) backbone N-Hs of Leu312 and Phe580 highlighted as residues to target in SBDD fragment growing designs at the 5-position of the 1-methyl-1*H*-benzo[*d*]imidazol-2-amine scaffold.

Table 4 Examples 22–27 designed, using SBDD, to target interactions with the free backbone N-Hs of either Leu312 or Phe580


Ex	R ₁	PRMT5/MTA <i>K</i> _D (μM)	LLE	clog <i>P</i>
22		1.48	4.5	1.3
23		1.02	4.3	1.7
24		0.057	5.1	2.1
25		0.205	5.8	0.9
26		0.179	5.9	0.8
27		0.008	5.5	2.6

shown in Fig. 11B. Thus, a series of analogs incorporating hydrogen bond acceptors designed to target a productive

interaction with either of the two available N-Hs were investigated as shown in Table 4.

To explore the 5-position vector of **13** a series of versatile synthetic routes and intermediates were developed as shown in Scheme 1. Examples 22–24 were prepared from the 6-bromo-2-(2,5-dimethylpyrrol-1-yl)-3-methyl-benzimidazole-4-carbonitrile intermediate **19**. Example 22 was synthesized *via* an Ullman coupling^{20,21} between pyridin-3-ol and **19** followed by removal of the 2,5-dimethylpyrrole protecting group under acidic conditions. Example 23 was prepared *via* bromolithium exchange of **19** with *n*-butyl lithium followed by quenching with 3-(3-pyridyldisulfanyl) pyridine. Subsequent removal of the 2,5-dimethylpyrrole protecting group under acidic conditions gave **23**. Example 24 was prepared from carboxylic acid **20** which was submitted to standard amide coupling conditions with aniline followed by removal of the 2,5-dimethylpyrrole protecting group under acidic conditions. **20** was prepared by bromo-lithium exchange of **19** with *n*-butyl lithium followed by quenching with 2-bromoacetic acid. Example 25 was accessed *via* Suzuki–Miyaura²² coupling between intermediate **21** and 3-(chloromethyl)-1-methylpyrazole followed by removal of the 2,5-dimethylpyrrole protecting group under acidic conditions. Examples 26 and 27 were prepared by the same method as example 25.

The synthetic routes described in Scheme 1 enabled the rapid preparation of approximately 150 analogs. Exemplar compounds, 22–27 (Table 4) were selected to highlight key



Scheme 1 Synthesis of compounds 22–27. (a) Pyridine-3-ol, 2-(dimethylamino)acetic acid Cul, K₃PO₄, DMSO, 120 °C, 64%; (b) 12 M HCl, EtOH, 120 °C, 21%; (c) 3-(3-pyridyldisulfanyl) pyridine, ⁿBuLi, THF, -65 °C – rt, 28%; (d) 12 M HCl, EtOH, 120 °C, 48%; (e) **20**, ⁿBuLi, 2-bromoacetic acid, THF, -65 °C – rt, 12%; (f) aniline, EDCI, HOBT, DIEA, DMF, rt, 89%; (g) TFA, 80 °C, 27%; (h) (chloromethyl)-R₁, Pd(dppf)Cl₂, K₂CO₃, DMF, 100 °C, 28–71%; (i) 12 M HCl, EtOH, 120 °C, 26–59%.

aspects of the SAR for this series. *O*-linked pyridin-3-yl example 22 did not increase potency significantly and compared to example 13 a slight reduction in LLE was observed (PRMT5/MTA $K_D = 1.48 \mu\text{M}$; $\Delta\text{LLE} = -0.3$). *S*-linked pyridin-3-yl example 23 behaved similarly to 22 (PRMT5/MTA $K_D = 1.02 \mu\text{M}$; $\Delta\text{LLE} = -0.5$). Meanwhile, *N*-phenylacetamide analog 24 increased potency by 39-fold and increased LLE (PRMT5/MTA $K_D = 0.057 \mu\text{M}$; $\Delta\text{LLE} = +0.3$). Methylene linked *N*-methyl pyrazole analogs 25 and 26 gave similar results to each other with a potency increase of 11-fold and together with a reduction in clog P this translated to a significantly higher LLE (PRMT5/MTA $K_D = 0.205 \mu\text{M}$ and $0.179 \mu\text{M}$; $\Delta\text{LLE} = +1.0$ and $+1.1$ respectively). The methylene linked analog 2-cyanobenzyl 27 was the most potent analog from this cohort (PRMT5/MTA $K_D = 0.008 \mu\text{M}$; $\Delta\text{LLE} = +0.7$). Fig. 12A–C show the three PRMT5/MTA X-ray co-crystal structures generated from this cohort of analogs. The X-ray co-crystal structure of 22 (PDB: 7ZV2, Fig. 12A) was the first X-ray co-crystal structure of the 1-methyl-1*H*-benzo[*d*]imidazol-2-amine scaffold

containing the nitrile substituent. The structure confirmed that the binding mode of 22 maintains the original binding mode of fragment hit 3, and the nitrile substituent indeed makes a favorable H-bond interaction with the Lys333 sidechain residue as predicted by molecular modeling. The pyridinyl nitrogen lone pair of 22 makes a productive H-bond interaction with the Phe580 backbone N-H and the oxygen linker makes a water bridged H-bond to the Leu312 backbone N-H. The X-ray co-crystal structures of 25 and 26 with PRMT5/MTA are shown in Fig. 12B (PDB: 7ZVU) and Fig. 12C (PDB: 7ZVY). The *N*-methylpyrazole lone pair of 25 makes a productive H-bond with the Leu312 backbone N-H while the *N*-methylpyrazole lone pair of 26 makes a water bridged H-bond with the Leu312 backbone N-H. It was notable that the 2-amino-1-methyl-1*H*-benzo[*d*]imidazol-7-carbonitrile scaffold remains in a constant position while the 5-position substituents scan a range of geometries and make a diverse set of interactions with the protein. This example highlights the value of obtaining X-ray structures




Fig. 12 (A) X-ray co-crystal structure of 22 bound to PRMT5/MTA (PDB: 7ZV2). (B) X-ray co-crystal structure of 25 bound to PRMT5/MTA (PDB: 7ZVU). (C) X-ray co-crystal structure of 26 bound to PRMT5/MTA (PDB: 7ZVY). (D) MOE model of compound 27 bound to PRMT5/MTA showing the 2-cyano phenyl substituent making a productive H-bond interaction with the Leu312 backbone N-H.

during a fragment elaboration campaign. An X-ray co-crystal structure of **27** bound to PRMT5/MTA was not obtained; therefore, **27** was modelled into the binding site using MOE, shown in Fig. 12D. The 2-amino-1-methyl-1H-benzo[d]imidazolo-7-carbonitrile scaffold was overlayed with the binding poses of **22**, **25** and **26** and molecular modeling indicated the 2-cyano phenyl substituent would make a productive H-bond interaction with the Leu312 backbone N-H.

Fragment hits 4 and 5 – series 4

We elected to focus on hit **4** with the option to transfer SAR to fragment hit **5** at a later timepoint. Therefore, in an analogous approach to the growing strategies of fragment hits **1** and **3** we envisioned a series of analogs branching off the 7-position of the 1,5-naphthyridin-2-amine fragment **4** scaffold. Versatile intermediates **28–31** (Fig. 13) were prepared, and a series of 50 analogs were synthesized using palladium-mediated and copper-mediated coupling chemistry (see ESI† for experimental details).

Exemplar compounds (**32–37**, Table 5) were selected to highlight key aspects of the SAR for this series. Thiazol-4-yl analog **32** increased potency 8-fold with no change in LLE indicating the increase in potency was lipophilicity driven (PRMT5/MTA K_D = 7.5 μM ; $\Delta\text{LLE} = 0.0$). Whereas *O*-linked pyridin-3-yl analog (**33**) increased potency 25-fold and increased LLE (PRMT5/MTA K_D = 1.5 μM ; $\Delta\text{LLE} = +1.0$). Methylene linked pyridin-3-yl and *N*-methyl pyrazol-4-yl analogs **34** and **35** increased potency 267-fold and 452-fold respectively and increased LLE (PRMT5/MTA K_D = 0.232 μM and 0.137 μM ; $\Delta\text{LLE} = +1.6$ and +2.8 respectively). An X-ray crystal structure of **34** was solved with PRMT5/MTA (PDB: 7ZUU) and is shown in Fig. 14A. The 1,5-naphthyridine scaffold remains in the same binding mode as the original fragment hit and the methylene linked pyridinyl nitrogen lone pair makes a productive H-bond interaction with the Leu312 backbone N-H. Interestingly the Ser578 loop moves and rotates away from the ligand in a fashion reminiscent of the loop conformation for the fragment hit **5** co-crystal structure, shown in Fig. 14B. Notably, the movement of the Phe577 side chain is more pronounced with **34** than what was previously observed. The movement of the Ser578 loop

Table 5 Examples **32–37**, fragment hit **4** growth designs at the 7-position of the 1,5-naphthyridin-2-amine scaffold

Ex	R ₁	clog P	PRMT5/MTA K_D (μM)	LLE
32		2.1	7.50	3.0
33		1.5	2.46	4.1
34		1.9	0.232	4.7
35		1.0	0.137	5.9
36		2.0	0.094	5.0
37		0.5	0.151	6.3

was not observed with fragment hits **1–3**, thus making the properties of the PRMT5 protein structure unique for the 1,5-naphthyridin-2-amine fragment scaffold. The chimeric approach described with fragment hit **1** was also applied to fragment hit **4**. This resulted in the identification of **36** and **37** with PRMT5/MTA K_D = 0.094 μM and PRMT5/MTA K_D = 0.151 μM respectively.

Discussion

A fragment screen to identify chemical matter for the PRMT5/MTA complex resulted in the discovery of five fragment hits whose binding modes were verified by co-crystal crystallography with PRMT5 in the presence of MTA. The five hits represented four distinct scaffolds. With no validated chemical matter reported in the literature at the time the project was initiated, these hits provided an




Fig. 13 Analogs to explore the SAR of fragment hit **4** were prepared from versatile intermediates **28–31**.






Fig. 14 A) X-ray co-crystal structure of **34** bound to PRMT5/MTA (PDB: 7ZUU) showing the methylene linked pyridine-3-yl lone pair making a productive H-bond interaction with the Leu312 backbone N-H. B) Overlay of **4** and **34** highlighting the movement of the Ser578 loop and sidechains.

opportunity to leverage both structure- and synthesis-enabled fragment elaboration strategies to identify potent compounds to further investigate the role of the PRMT5/MTA complex in cancer biology. Fragment elaboration strategies were investigated for each scaffold, ultimately resulting in the identification of two lead series, from fragment hit **2** and fragment hit **3**.

The chemistry for fragment hit **1** was challenging to develop; therefore, a bespoke set of compounds were designed *via* a chimeric approach with a known PRMT5 inhibitor EPZ015666, although 666 binds to PRMT5 in an alternative binding mode. Two X-ray crystal structures were obtained *via* this approach and demonstrated the original fragment binding mode was retained in the elaborated molecules. Compound **9** was the most potent example with PRMT5/MTA K_D = 9 nM, LLE = 7.4 and Δ LLE = +2.4, and this molecule highlighted the importance of an H-bond interaction with Leu312 to improve potency.

The chemistry for fragment hit **2** was readily accessible and a viable vector was rapidly identified. Compound **11** was the most potent example identified in the first round of fragment elaborations (PRMT5/MTA K_D = 5 nM, LLE = 8.4 and Δ LLE = +3.5). An X-ray co-crystal structure with **11** was obtained demonstrating the binding mode of the original fragment hit was conserved and additional vectors for further growth were clearly identified to support additional rounds of SAR. Ultimately, this series gave rise to the discovery of clinical candidate MRTX1719 (Fig. 1).⁵

Fragment hit **3** was first optimized before examination of the fragment growth SAR. Fragment analog **13** was identified with improved potency and LLE compared to the starting fragment hit **3**. The synthetic chemistry for fragment growth was enabled *via* several versatile synthetic intermediates developed from fragment **13**. A series of 150 analogs were investigated. Compound **27** was the most potent example

identified with a PRMT5/MTA K_D = 8 nM, LLE = 5.5 and Δ LLE = +2.3. Four additional X-ray structures were discovered in this series, each demonstrating that the original fragment binding mode was conserved and additional vectors for further growth were clearly identified to support further rounds of fragment growing SAR (not reported here).

Finally, the chemistry for fragment hit **4** was also enabled *via* a series of versatile intermediates **28–31**. Example **36** was the most potent example identified, with PRMT5/MTA K_D = 94 nM, LLE = 5.0 and Δ LLE = +1.9. An X-ray structure was determined with example **34** which highlighted protein movements in the Ser578 loop. It remains unclear if protein mobility in the Ser578 loop would be an advantage by creating a new pocket to grow into, or a disadvantage by introducing ambiguity into the SBDD molecular modeling. Although the original intention was to examine if the SAR would transfer from fragment **4** to fragment **5** or if the SAR would be divergent, we decided to not perform this exercise but to focus efforts on driving forward series **2** and series **3**.

Conclusions

Starting with five fragment hits, each with a clear binding orientation in a PRMT5/MTA co-crystal structure, we embarked on a round of fragment elaboration to generate a dataset with the objective of answering three questions designed to help prioritize the fragment hit series: could the binding potency be improved? Were the series chemically tractable? Could additional co-crystal structures be solved? We discovered that the potency and LLE could be improved for hits **1–4**. Indeed, examples with sub-10 nM K_D s were discovered for series **1–3**, while the most potent example from series **4** was approximately 10-fold weaker. Chemistry enablement and access to versatile intermediates was achieved for hits **2–4**. The chemistry was challenging



for hit **1**, and access to versatile intermediates to probe the vectors of interest was not enabled. Crystallography enablement to support SBDD was excellent for series **1–3**, while there were questions raised for series **4** related to protein flexibility and movement of the Ser578 loop. With these data in hand, series **2** and series **3** scored most favorably across the three proposed questions. Thus, these two series were selected as lead series for further optimization. Ultimately, a clinical candidate was discovered from hit series **2** and is currently in a phase 1/2 clinical study in solid tumors with *MTAP* deletion.²³

Experimental

Chemistry

General experimental. All chemicals were purchased from commercial suppliers and used as received unless otherwise indicated. Nuclear magnetic resonance (NMR) spectroscopy was performed on a Bruker Avance III 400 MHz spectrometer, where proton NMR (¹H NMR) spectra and carbon NMR (¹³C NMR) spectra acquired at 400 and 101 MHz respectively. All spectra were recorded in deuterated dimethyl sulfoxide (DMSO-*d*₆), deuterated methanol (CD₃OD-*d*₄) or deuterated chloroform (CDCl₃) obtained from Cambridge Isotope Laboratories Inc. Chemical shifts (δ) were measured in parts per million (ppm) and referenced against the internal reference peaks. Coupling constants (J), when given, are reported in hertz. Multiplicities are reported using the following abbreviations: s = singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, m = multiplet (range of multiplet is given), br = broad signal, dt = doublet of triplets. Final Compounds were purified by reverse phase high-performance liquid chromatography (*prep*-HPLC) by either of the following conditions: HCl condition – Phenomenex Luna C18 75 × 30 mm × 3 μ m; mobile phase: [water (0.05% HCl)-ACN]; *B*%: 10–40%, 6.5 min. Basic condition – Waters Xbridge 150 × 25 mm × 5 μ m; mobile phase: [water (0.05% ammonia hydroxide v/v)-acetonitrile]; *B*%: 3–40%, 10 min. Ammonium bicarbonate condition – Waters Xbridge 150 × 25 mm × 5; mobile phase: water (10 mM ammonium bicarbonate)-acetonitrile; *B*: 2–40%, 10 min. The purity for test compounds was determined by high-performance liquid chromatography (HPLC) on a LC-20AB Shimadzu instrument. HPLC conditions were as follows: Kinetex C18 LC Column 4.6 × 50 mm, 5 μ m, 10–80% ACN (0.0375% TFA) in water (0.01875% TFA), 4 min run, flow rate 1.5 mL min⁻¹, UV detection (λ = 220, 215, 254 nm) or XBridge C18, 2.1 × 50 mm, 5 μ m, 10–80% ACN in water buffered with 0.025% ammonia, 4 min run, flow rate 0.8 mL min⁻¹, UV detection (λ = 220, 215, 254 nm), or Kinetex EVO C18 100 × 4.6 mm, 2.6 μ m, 0–60% (or 10–80%) ACN (0.0375% TFA) in water (0.01875% TFA) 10 min run, flow rate 1.0 mL min⁻¹, UV detection (λ = 220, 254 nm) or Eclipse plus C18 150 × 4.6 mm, 3.5 μ m, 10–80% ACN (0.0375% TFA) in water (0.01875% TFA) 15 min run, flow rate 1.0 mL min⁻¹, UV detection (λ = 220, 254 nm). The mass spectra were obtained

using liquid chromatography mass spectrometry (LCMS) on a LCMS-2020 Shimadzu instrument using electrospray ionization (ESI). LCMS conditions were as follows: Kinetex EVO C18 30 × 2.1 mm, 5 μ m, 5–95% ACN (0.0375% TFA) in water (0.01875% TFA), 1.5 min run, flow rate 1.5 mL min⁻¹, UV detection (λ = 220, 254 nm), or Kinetex EVO C18 2.1 × 30 mm, 5 μ m, 5–95% ACN in water buffered with 0.025% ammonia, 1.5 min run, flow rate 1.5 mL min⁻¹, UV detection (λ = 220, 254 nm). High resolution mass measurements were carried out on an Agilent 1290LC & 6530Q-TOF series with ESI. All compounds are >95% pure by HPLC.

Examples **1–5**, **12** and **14–18** were commercially available. Intermediate **10** and Example **11** were previously described.⁵ Preparation of intermediates **19**, **21** and **28–31** and examples **6–9**, **13** and **32–37** are described in the ESI.[†] Examples **22–27** were prepared according to Scheme 1 and the procedures are described below.

2-Amino-3-methyl-6-(3-pyridyloxy)benzimidazole-4-carbonitrile (22)

Step a. To a solution of **19** (150 mg, 455 μ mol, 1.00 eq.), pyridin-3-ol (130 mg, 1.37 mmol, 3.00 eq.) and 2-(dimethylamino)acetic acid (18.8 mg, 182 μ mol, 0.40 eq.) in DMSO (3.0 mL) was added copper iodide (17.4 mg, 91.1 μ mol, 0.20 eq.) and potassium phosphate (290 mg, 1.37 mmol, 3.00 eq.). The mixture was stirred at 120 °C for 16 h. After such time the reaction was poured into water (20 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic layers were concentrated and the residue purified by silica gel chromatography (ethyl acetate in petroleum ether gradient 0–100%) to give 2-(2,5-dimethylpyrrol-1-yl)-3-methyl-6-(3-pyridyloxy)benzimidazole-4-carbonitrile (100 mg, 291 μ mol, 64% yield) as a yellow solid. LCMS [M + 1]⁺: 344.2.

Step b. To a solution of 2-(2,5-dimethylpyrrol-1-yl)-3-methyl-6-(3-pyridyloxy)benzimidazole-4-carbonitrile (50 mg, 146 μ mol, 1.00 eq.) in ethanol (1.5 mL) was added hydrochloric acid (12 M, 375 μ L). The mixture was microwave heated at 120 °C in a sealed microwave vial for 2 h. The cooled mixture was then treated with ammonium hydroxide (0.1 mL) to adjust the pH to 7. The mixture was then concentrated and the residue purified by *prep*-HPLC (ammonium bicarbonate condition) to give 2-amino-3-methyl-6-(3-pyridyloxy)benzimidazole-4-carbonitrile, **22** (8.3 mg, 30.6 μ mol, 21% yield) as a white solid. LCMS [M + 1]⁺: 266.0; ¹H NMR (400 MHz, CD₃OD-*d*₄) δ = 8.32–8.24 (m, 2H), 7.41 (d, J = 1.6, 3.2 Hz, 2H), 7.16 (d, J = 2.4 Hz, 1H), 7.05 (d, J = 2.4 Hz, 1H), 3.85 (s, 3H); HRMS (ESI, +ve ion) *m/z* calcd for C₁₄H₁₁N₅O 265.0964; found 265.0949; HPLC Rt 0.582 min, 96.8%.

2-Amino-3-methyl-6-(3-pyridylsulfanyl)benzimidazole-4-carbonitrile hydrochloride (22)

Step c. To a solution of **19** (100 mg, 303 μ mol, 1.00 eq.) in THF (2.0 mL) was added *n*-butyllithium (2.50 M, 145 μ L, 1.20 eq.) at -65 °C. The mixture was stirred at -65 °C for 0.5 h. A solution of 3,3'-dithiodipridine (80 mg, 364 μ mol, 1.20 eq.) in THF (0.5 mL) was then added at -65 °C. The mixture was stirred at -65 °C for 0.5 h, then warmed up slowly to 25



°C and stirred for an additional 0.5 h. The mixture was diluted with saturated ammonium chloride (50 mL), extracted with ethyl acetate (50 mL), dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography with (ethyl acetate in petroleum ether 0–50%) to afford 2-(2,5-dimethylpyrrol-1-yl)-3-methyl-6-(3-pyridylsulfanyl)benzimidazole-4-carbonitrile (37 mg, 85.4 µmol, 28% yield) as a yellow gum. LCMS [M + 1]⁺: 360.1.

Step d. To a solution of 2-(2, 5-dimethylpyrrol-1-yl)-3-methyl-6-(3-pyridylsulfanyl)benzimidazole-4-carbonitrile (32 mg, 89.0 µmol, 1.0 eq.) in ethyl alcohol (0.5 mL) was added 12 M hydrochloric acid (0.05 mL, 503 µmol, 5.6 eq.). The mixture was stirred at 120 °C in a microwave reactor for 1 h and then concentrated. The residue was purified by *prep*-HPLC (HCl condition) to afford 2-amino-3-methyl-6-(3-pyridylsulfanyl)benzimidazole-4-carbonitrile hydrochloride, **23** (13.9 mg, 43.1 µmol, 48% yield) as a white solid. LCMS [M + 1]⁺: 282.0. ¹H NMR (400 MHz, CD₃OD-*d*₄) δ = 8.72 (s, 1H), 8.69 (br d, *J* = 5.2 Hz, 1H), 8.37 (br d, *J* = 8.0 Hz, 1H), 7.98 (s, 2H), 7.94 (s, 1H), 3.99 (s, 3H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ = 152.40, 147.62, 146.03, 141.23, 134.75, 132.39, 132.18, 131.69, 127.60, 126.12, 120.43, 115.65, 95.29, 30.87; HRMS (ESI, +ve ion) *m/z* calcd for C₁₄H₁₁N₅S 281.0735; found 281.0720; HPLC Rt 0.863 min, 97.5%.

2-(2-Amino-7-cyano-1-methyl-benzimidazol-5-yl)-N-phenyl-acetamide hydrochloride (24)

Step e. To a mixture of **19** (300 mg, 911 µmol, 1.0 eq.) in THF (4.0 mL) at -60 °C under nitrogen atmosphere was added *n*-butyllithium (2.50 M, 729 µL, 2.0 eq.). The mixture was stirred at -60 °C for 0.5 hour. Then 2-bromoacetic acid (506 mg, 3.65 mmol, 262 µL, 4.0 eq.) in tetrahydrofuran (1.0 mL) was added and the resulting mixture was warmed up to 30 °C and stirred for an additional 0.5 hour. The reaction mixture was quenched with water (1.0 mL) and purified by *prep*-HPLC (formic acid condition) to afford 2-[7-cyano-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-5-yl]acetic acid (35 mg, 106 µmol, 12% yield) as a white solid. LCMS [M + 1]⁺: 309.2. ¹H NMR (400 MHz, CD₃OD-*d*₄) δ = 7.95 (d, *J* = 1.2 Hz, 1H), 7.75 (d, *J* = 1.2 Hz, 1H), 5.98 (s, 2H), 3.83 (s, 2H), 3.77 (s, 3H), 2.04 (s, 6H).

Step f. To a mixture of 2-[7-cyano-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-5-yl]acetic acid (35 mg, 114 µmol, 1.0 eq.) and aniline (31 µL, 340 µmol, 3.0 eq.) in DMF (1.0 mL) was added *N*-(3-dimethylaminopropyl)-*N*-ethylcarbodiimide hydrochloride (33 mg, 170 µmol, 1.50 eq.), 1-hydroxybenzotriazole (23 mg, 170 µmol, 1.5 eq.) and *N,N*-diisopropylethylamine (340 µmol, 59.3 µL, 3.0 eq.). The mixture was stirred at 30 °C for 16 hours. The reaction mixture was concentrated and purified by *prep*-TLC (SiO₂, petroleum ether/ethyl acetate 3 : 1) to afford 2-[7-cyano-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-5-yl]-*N*-phenyl-acetamide (40 mg, 100 µmol, 89% yield) as a yellow oil. LCMS [M + 1]⁺: 384.3. ¹H NMR (400 MHz, CDCl₃) δ = 8.01 (d, *J* = 1.2 Hz, 1H), 7.71 (d, *J* = 1.2 Hz, 1H), 7.48 (d, *J* = 7.6 Hz, 2H), 7.33–7.29 (m, 3H), 7.17–7.09 (m, 1H), 5.98 (s, 2H), 3.87 (s, 2H), 3.74 (s, 3H), 2.05 (s, 6H).

Step g. A mixture of 2-[7-cyano-2-(2,5-dimethylpyrrol-1-yl)-1-methyl-benzimidazol-5-yl]-*N*-phenyl-acetamide (30 mg, 78.2 µmol, 1.0 eq.) in trifluoroacetic acid (2.0 mL) was stirred at 80 °C for 16 hours. The mixture was concentrated. The crude was purified by *prep*-HPLC (HCl condition) to afford 2-(2-amino-7-cyano-1-methyl-benzimidazol-5-yl)-*N*-phenyl-acetamide hydrochloride, **24** (7.5 mg, 21.4 µmol, 27% yield) as a light green solid. LCMS [M + 1]⁺: 306.2. ¹H NMR (400 MHz, CD₃OD-*d*₄) δ = 7.66 (dd, *J* = 1.2, 14.8 Hz, 2H), 7.55 (dd, *J* = 1.2, 8.8 Hz, 2H), 7.35–7.25 (m, 2H), 7.13–7.05 (m, 1H), 3.93 (s, 3H), 3.84 (s, 2H); HRMS (ESI, +ve ion) *m/z* calcd for C₁₇H₁₅N₅O 305.1277; found 305.1251; HPLC Rt 2.088 min, 97.8%.

General method for the preparation of examples 25–28 (Scheme 1)

To a solution of **21** (1.00 eq.) and R₁-Cl (1.5 eq.) in DMF (2.0 mL) was added potassium carbonate (3.0 eq.), followed by [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.15 eq.) under a nitrogen atmosphere. The mixture was then stirred at 100 °C for 16 hours. After such time the cooled reaction mixture was concentrated, and the residue purified by flash silica gel chromatography to afford an intermediate product. To a solution of this intermediate product in ethanol (1.0 mL) was added hydrochloric acid (12 M, 7 eq.). The mixture was stirred at 120 °C for 1.5 hours in a microwave reactor. The mixture was basified with ammonium hydroxide until pH 8 and concentrated in vacuum. The residue was purified by *prep*-HPLC (ammonium bicarbonate condition) to give the desired product.

2-Amino-3-methyl-6-[(1-methylpyrazol-3-yl)methyl]-benzimidazole-4-carbonitrile (25). Prepared according to the general method with **21** (50 mg, 133 µmol, 1.00 eq.) and 3-(chloromethyl)-1-methyl-pyrazole (26.0 mg, 199 µmol, 1.50 eq.) to afford **25** as a white solid (5.6 mg, 21 µmol, 15% yield over 2 steps). LCMS [M + 1]⁺: 267.1; ¹H NMR (400 MHz, CD₃OD-*d*₄) δ = 7.47 (d, *J* = 2.0 Hz, 1H), 7.32 (s, 1H), 7.14 (s, 1H), 6.04 (d, *J* = 2.0 Hz, 1H), 3.97 (s, 2H), 3.84 (s, 3H), 3.81 (s, 3H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ = 157.50, 151.26, 144.71, 133.79, 133.74131.71, 122.95, 120.29, 118.04, 104.63, 90.25, 38.65, 33.88, 29.89; HRMS (ESI, +ve ion) *m/z* calcd for C₁₄H₁₄N₆ 266.1280; found 266.1263; HPLC Rt 1.394 min, 95.9%.

2-Amino-3-methyl-6-[(1-methylpyrazol-4-yl)methyl]-benzimidazole-4-carbonitrile (26). Prepared according to the general method with **21** (120 mg, 319 µmol) and 4-(chloromethyl)-1-methyl-pyrazole (80 mg, 478 µmol, 1.50 eq.), to afford **26** as a white solid (13.6 mg, 51 µmol, 16% yield over 2 steps). LCMS [M + 1]⁺: 267.1; ¹H NMR (400 MHz, CD₃OD-*d*₄) δ = 7.38 (s, 1H), 7.33–7.26 (m, 2H), 7.11 (d, *J* = 1.56 Hz, 1H), 3.84 (s, 2H), 3.82 (s, 3H), 3.79 (s, 3H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ = 157.50, 144.80, 138.50, 135.18, 133.69, 129.58, 122.69, 120.76, 120.03, 118.05, 90.29, 38.80, 29.89, 29.79; HRMS (ESI, +ve ion) *m/z* calcd for C₁₄H₁₄N₆ 266.1280; found 266.1262; HPLC Rt 1.395 min, 99.7%.



2-Amino-6-[(2-cyanophenyl)methyl]-3-methylbenzimidazole-4-carbonitrile (27). Prepared according to the general method with 21 (100 mg, 274 μ mol) and 2-(chloromethyl)benzonitrile (91 mg, 598 μ mol, 1.50 eq.), to afford 27 as a white solid (47 mg, 167 μ mol, 61% yield over 2 steps). LCMS [M + 1]⁺: 288.2; ¹H NMR (400 MHz, CD₃OD-*d*₄) δ = 7.73 (dd, *J* = 1.1, 7.6 Hz, 1H), 7.69–7.62 (m, 1H), 7.57–7.49 (m, 3H), 7.45 (dt, *J* = 1.2, 7.6 Hz, 1H), 4.34 (s, 2H), 3.92 (s, 3H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ = 152.04, 144.13, 135.64, 134.17, 133.69, 131.35, 130.83, 130.64, 128.11, 128.00, 118.39, 117.04, 116.36, 111.94, 93.91, 38.77, 30.75; HRMS (ESI, +ve ion) *m/z* calcd for C₁₇H₁₃N₅ 287.1171; found 287.1149; HPLC Rt 1.486 min, 98.0%.

Biology

Methods and procedures for protein expression and purification for crystallography, protein expression and purification for SPR and *K*_D determination by SPR were previously described.⁵

Accession codes

Atomic coordinates for the X-ray structures of 1 (PDB 8CSG) 3 (PDB SCTB), 4 (PDB 7UYF), 5 (PDB 7UY1), 7 (PDB 7ZVL), 9 (PDB 4X61), 18 (PDB 7ZUP) 22 (PDB 7ZV2), 25 (PDB 7ZVU), 26 (PDB 7ZUY) and 34 (PDB 7ZUU) bound to PRMT5-MTA are available from the RCSB Protein Databank (<https://www.rcsb.org>).

Author contributions

CRS and SK coordinated the project and performed compound design and synthesis; MUDA, VA, RJG and NCT designed and performed protein preparation, protein-ligand crystallization, and crystallography; JGC conceived of the project; AI, and JDL performed compound design and computational studies; JMK, JK and XW performed compound design and synthesis; MAM conceived of the project and performed compound design and synthesis.

Conflicts of interest

There are no conflicts of interest to declare.

Acknowledgements

We would like to thank the following teams/people for their valuable contributions to this work. The IDSU chemistry team (WuXi AppTec in Wuhan, China): Tao Guo, Duan Liu, Song Mo. CSU chemistry team (WuXi AppTec in Wuhan, China): Rongfeng Zhao, Shaojun Song, Wenbing Ruan. *In vitro* ADME team and the RSD biology team (WuXi AppTec in Shanghai, China). Ronald Jean-Baptiste and Masakazu Kobayashi (ZoBio BV, J.H. Oortweg 19, 2333 CH Leiden, Netherlands) for the SPR PRMT5/MTA binding *K*_D determinations and Wolfgang Komel (ZoBio BV, J.H. Oortweg 19, 2333 CH Leiden, Netherlands) for preparing the PDB scripts and f factor files. Stephan Krapp and Brantley Haigh (Proteros Biostructures

GmbH, Bunsenstraße 7a, 82152 Planegg, Germany) for early enablement of X-ray crystallography. The X-ray crystallography work presented herein is based upon research conducted at the Northeastern Collaborative Access Team beamlines, which are funded by the National Institute of General Medical Sciences from the National Institutes of Health (P30 GM124165). The Eiger 16M detector on the 24-ID-E beam line is funded by a NIH-ORIP HEI grant (S10OD021527). This research used resources of the Advanced Photon Source, a U. S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357. We acknowledge the Paul Scherrer Institute, Villigen, Switzerland for provision of synchrotron radiation beamtime at beamlines PXII/X10SA and PXIII/X06DA of the SLS. The authors would like to thank Diamond Light Source for beamtime and the staff of beamline I03 for assistance with crystal testing and data collection. The research was funded by Mirati Therapeutics.

References

- 1 M. T. Bedford and S. G. Clarke, Protein arginine methylation in mammals: who, what, and why, *Mol. Cell*, 2009, 33(1), 1–13.
- 2 G. V. Kryukov, F. H. Wilson, J. R. Ruth, J. Paultk, A. Tsherniak, S. E. Marlow, F. Vazquez, B. A. Weir, M. E. Fitzgerald, M. Tanaka, C. M. Bielski, J. M. Scott, C. Dennis, G. S. Cowley, J. S. Boehm, D. E. Root, T. R. Golub, C. B. Clish, J. E. Bradner, W. C. Hahn and L. A. Garraway, MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells, *Science*, 2016, 351(6278), 1214–1218.
- 3 K. Marjon, M. J. Cameron, P. Quang, M. F. Clasquin, E. Mandley, K. Kunii, M. McVay, S. Choe, A. Kurnytsky, S. Gross, Z. Konteatis, J. Murtie, M. L. Blake, J. Travins, M. Dorsch, S. A. Biller and K. M. Marks, MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis, *Cell Rep.*, 2016, 15(3), 574–587.
- 4 K. J. Mavrakis, E. R. McDonald, 3rd, M. R. Schlabach, E. Billy, G. R. Hoffman, A. deWeck, D. A. Ruddy, K. Venkatesan, J. Yu, G. McAllister, M. Stump, R. deBeaumont, S. Ho, Y. Yue, Y. Liu, Y. Yan-Neale, G. Yang, F. Lin, H. Yin, H. Gao, D. R. Kipp, S. Zhao, J. T. McNamara, E. R. Sprague, B. Zheng, Y. Lin, Y. S. Cho, J. Gu, K. Crawford, D. Ciccone, A. C. Vitari, A. Lai, V. Capka, K. Hurov, J. A. Porter, J. Tallarico, C. Mickanin, E. Lees, R. Pagliarini, N. Keen, T. Schmelzle, F. Hofmann, F. Stegmeier and W. R. Sellers, Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5, *Science*, 2016, 351(6278), 1208–1213.
- 5 C. R. Smith, R. Aranda, T. P. Bobinski, D. M. Briere, A. C. Burns, J. G. Christensen, J. Clarine, L. D. Engstrom, R. J. Gunn, A. Ivetac, R. Jean-Baptiste, J. M. Ketcham, M. Kobayashi, J. Kuehler, S. Kulyk, J. D. Lawson, K. Moya, P. Olson, L. Rahbaek, N. C. Thomas, X. Wang, L. M. Waters and M. A. Marx, Fragment-Based Discovery of MRTX1719, a



Synthetic Lethal Inhibitor of the PRMT5*MTA Complex for the Treatment of MTAP-Deleted Cancers, *J. Med. Chem.*, 2022, **65**(3), 1749–1766.

6 J. R. Allen, A. Amegadzie, D. J. Beylkin, S. Booker, M. P. Bourbeau, J. R. Butler, M. J. Frohn, S. O. S. Glad, B. W. Husemoen, M. R. Kaller, J. R. Butler, M. J. Frohn, S. O. S. Glad, B. W. Husemoen, M. R. Kaller, T. J. Kohn, B. A. Lanman, K. Li, Q. Liu, P. Lopez, V. V. Ma, F. Manoni, J. Medina, A. E. Minatti, J. Peiro Cadahia, L. Pettus, A. J. Pickrell, I. Sarvary, N. A. Tamayo and M. Vestergaard, *Preparation of naphthyridinecarboxamide and quinolinicarboxamide compounds as PRMT5 inhibitors*, WO2021163344, 2021.

7 K. M. Cottrell and J. P. Maxwell, *Piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP-deficient and/or MTA accumulating cancers and their preparation*, WO2022026892, 2022.

8 D. A. Erlanson, S. W. Fesik, R. E. Hubbard, W. Jahnke and H. Jhoti, Twenty years on: the impact of fragments on drug discovery, *Nat. Rev. Drug Discovery*, 2016, **15**(9), 605–619.

9 A. R. Leach, M. M. Hann, J. N. Burrows and E. J. Griffen, Fragment screening: an introduction, *Mol. BioSyst.*, 2006, **2**(9), 430–446.

10 M. Congreve, R. Carr, C. Murray and H. Jhoti, A 'rule of three' for fragment-based lead discovery?, *Drug Discovery Today*, 2003, **8**(19), 876–877.

11 J. B. Baell and G. A. Holloway, New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays, *J. Med. Chem.*, 2010, **53**(7), 2719–2740.

12 S. B. Shuker, P. J. Hajduk, R. P. Meadows and S. W. Fesik, Discovering high-affinity ligands for proteins: SAR by NMR, *Science*, 1996, **274**(5292), 1531–1534.

13 A. L. Hopkins, C. R. Groom and A. Alex, Ligand efficiency: a useful metric for lead selection, *Drug Discovery Today*, 2004, **9**(10), 430–431.

14 P. D. Leeson and B. Springthorpe, The influence of drug-like concepts on decision-making in medicinal chemistry, *Nat. Rev. Drug Discovery*, 2007, **6**(11), 881–890.

15 D. Chandler, Interfaces and the driving force of hydrophobic assembly, *Nature*, 2005, **437**(7059), 640–647.

16 J. D. St Denis, R. J. Hall, C. W. Murray, T. D. Heightman and D. C. Rees, Fragment-based drug discovery: opportunities for organic synthesis, *RSC Med. Chem.*, 2020, **12**(3), 321–329.

17 *Molecular Operating Environment (MOE)*, Chemical Computing Group, 2020.

18 K. W. Duncan, N. Rioux, P. A. Boriack-Sjodin, M. J. Munchhof, L. A. Reiter, C. R. Majer, L. Jin, L. D. Johnston, E. Chan-Penebre, K. G. Kuplast, M. Porter Scott, R. M. Pollock, N. J. Waters, J. J. Smith, M. P. Moyer, R. A. Copeland and R. Chesworth, Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666, *ACS Med. Chem. Lett.*, 2016, **7**(2), 162–166.

19 E. Chan-Penebre, K. G. Kuplast, C. R. Majer, P. A. Boriack-Sjodin, T. J. Wigle, L. D. Johnston, N. Rioux, M. J. Munchhof, L. Jin, S. L. Jacques, K. A. West, T. Lingaraj, K. Stickland, S. A. Ribich, A. Raimondi, M. P. Scott, N. J. Waters, R. M. Pollock, J. J. Smith, O. Barbash, M. Pappalardi, T. F. Ho, K. Nurse, K. P. Oza, K. T. Gallagher, R. Kruger, M. P. Moyer, R. A. Copeland, R. Chesworth and K. W. Duncan, A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models, *Nat. Chem. Biol.*, 2015, **11**(6), 432–437.

20 F. Ullmann and J. Bielecki, Ueber Synthesen in der Biphenylreihe, *Chem. Ber.*, 1901, **34**(2), 2174–2185.

21 S. V. Ley and A. W. Thomas, Modern synthetic methods for copper-mediated C(aryl)[bond]O, C(aryl)[bond]N, and C(aryl)[bond]S bond formation, *Angew. Chem., Int. Ed.*, 2003, **42**(44), 5400–5449.

22 N. Miyaura and A. Suzuki, Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds, *Chem. Rev.*, 1995, **95**, 2457–2483.

23 NCT05245500, <https://clinicaltrials.gov>.

